This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cancer drug developer Merrimack Pharmaceuticals Inc. has netted $95.6mm through its initial public offering by selling 14.3mm common shares at $7. The company originally filed in August 2011 and announced in January 2012 that it hoped to sell 16.67mm shares between $8-10 apiece. Shortly thereafter, there was speculation that Merrimack would postpone or withdraw its filing due to market conditions, but an accelerated S1 approval led the company to a successful pricing.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?